Use of a Reference Material to Evaluate Analytical Methods for the Determination of Plasma Lipoprotein(a)

This international laboratory comparison study evaluated a proposed IFCC reference material for standardizing Lp(a) measurement across assay platforms — a necessary step if Lp(a) results are to be meaningfully compared across laboratories, clinical trials, and healthcare systems.

Thirty serum samples were measured by multiple methods across multiple laboratories. Between-laboratory coefficients of variation for clinical samples ranged from 6 to 31 percent — unacceptably high for a biomarker intended to guide clinical decisions. This variability directly reflected assay sensitivity to apo(a) isoform size heterogeneity: methods using antibodies against the variable kringle IV repeat region produced systematically discordant results despite being calibrated against the same reference material.

The clinical consequence is not abstract. If two laboratories measure the same patient’s Lp(a) using different assay methods, results may differ by 30 percent — enough to shift interpretation of cardiovascular risk or eligibility for treatment. Standardization determines whether a clinical threshold (such as >50 mg/dL or >100 nmol/L) means the same thing across healthcare settings. This study established the technical case for moving to isoform-insensitive assays and nmol/L reporting, now recommended by international consensus.

We rate the evidence strong, with high clinical significance. A definitive international methods study establishing the standardization challenge for Lp(a) measurement — foundational to the field’s ongoing transition toward accurate, comparable Lp(a) quantification in clinical practice.